Ann: OncoSil AGM CEO Presentation, page-108

yes your comments are balanced and appreciated. Biotech is inherently risky but sometimes there is evidence that does support conviction investing notwithstanding. The last time I had this strong a conviction was with Avita in Sept | Oct 2017. The conviction evidence Included some very credible Australian scientists and also the very obvious compassion inherent in the product, not emotion but the fundamental of medicine is to alleviate suffering, where instead of slicing huge slabs of skins, patients were able to receive effective burns treatment with a much smaller graft zone. That company is now ASX200. Recent post mortem studies indicate upto 30% of PC deaths occur where the tumours are completely within the pancreas. For 30% of these patients at least the product has the ability to increase the odds of resection from approx 15% to approx 25% with clear margins. The case studies report that the implant is a comfortable procedure and tolerable for the patient. This within a device where the FDA is completely comfortable approving a 3 years payload of medicine into the eye. The science underpinning the device and the organisations where invention took place is at least / has at least the reputable value of Dr Fiona Wood. That was another company where developments and approvals took longer than expected